Lorazepam ๐
๐ก Key Safety Point: Oversedation and respiratory depression are the major concerns - particularly with IV or IM use.
๐ฉบ Always ensure facilities for airway support, oxygen, and resuscitation are available before administration.
๐ง About
- Lorazepam is a short-acting benzodiazepine used for acute seizure control, sedation, and anxiety.
- Compared with diazepam, it has a slower onset but longer duration of CNS activity, as it binds more avidly to GABAA receptors and redistributes more slowly.
- It is metabolised hepatically by conjugation (not oxidation), so preferred in liver impairment.
โ๏ธ Mechanism of Action
- Enhances the effect of gamma-aminobutyric acid (GABA) at the GABAA receptor.
- Increases chloride ion influx, hyperpolarising neuronal membranes and reducing excitability.
- Produces anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
๐ฏ Indications
- โก Status epilepticus (first-line benzodiazepine for IV use in the UK).
- ๐ Acute agitation or violent behaviour in psychiatric or medical settings.
- ๐ Acute anxiety or pre-operative sedation.
- ๐ค Insomnia associated with anxiety.
๐ Typical Doses
- Status epilepticus: Lorazepam 2โ4 mg slow IV over 1 minute into a large vein; may repeat once after 10โ15 minutes if seizures persist.
Flush line with 0.9% saline before and after to avoid precipitation.
- Acute agitation: Lorazepam 1โ2 mg IV or IM; slower absorption by IM route, duration 4โ6 hours.
- Anxiety / sedation: 1โ2 mg PO/IM/IV up to BD; elderly start at 0.5โ1 mg BD.
- Insomnia (short-term): 1โ2 mg PO at bedtime.
๐ Dose Range (Always Check BNF or Datasheet)
| Indication | Typical Dose | Frequency | Route |
| Status epilepticus | 2โ4 mg | Once; repeat after 10โ15 min if needed | Slow IV |
| Acute anxiety | 1โ4 mg/day | In 1โ2 divided doses | PO / IM |
| Elderly or frail | 0.5โ1 mg | BD | PO / IM |
๐ Interactions
- ๐น Sodium valproate: reduce lorazepam dose by 50% (valproate impairs lorazepam clearance).
- ๐น Other CNS depressants (alcohol, opioids, antihistamines): additive sedation and respiratory depression.
- ๐น Flumazenil reverses effects but may provoke rebound seizures in epileptic patients - use with extreme caution.
โ ๏ธ Cautions
- Ensure resuscitation and airway equipment are available before parenteral use.
- Use lower doses in elderly and hepatic impairment.
- Risk of dependence and withdrawal phenomena with prolonged use.
- Avoid long-term use for insomnia or anxiety unless under specialist supervision.
๐ซ Contraindications
- Severe respiratory depression or sleep apnoea.
- Unstable myasthenia gravis (worsens muscle weakness).
- Severe COPD with COโ retention.
- Chronic psychosis or untreated depression (may exacerbate).
- Acute intoxication with alcohol or CNS depressants.
๐ฅ Adverse Effects
- ๐ซ Respiratory depression - most serious risk (esp. with IV).
- ๐ง Amnesia (anterograde), confusion, drowsiness, fatigue, ataxia.
- ๐ Hypotension, bradycardia (with rapid IV administration).
- ๐ Vertigo, headache, paradoxical agitation (esp. in elderly or children).
- ๐ Dependence and withdrawal symptoms with chronic use.
๐งพ Monitoring
| Parameter | Baseline | During Therapy |
| Respiratory rate and oxygen saturation | โ๏ธ Before IV/IM use | โ๏ธ Continuous until fully alert |
| BP and pulse | โ๏ธ | โ๏ธ Observe for hypotension or bradycardia |
| Level of consciousness | โ๏ธ | โ๏ธ Regular observation post-dose |
๐ก Teaching Tip
- Contrast lorazepamโs pharmacokinetics with diazepam: lorazepam redistributes more slowly and is metabolised by conjugation โ longer clinical effect despite shorter half-life.
- In status epilepticus, itโs the drug of choice due to prolonged CNS activity and lower fat solubility (less redistribution out of the brain).
- Always emphasise airway safety - the best anticonvulsant is useless if the patient becomes hypoxic.
- Review dependence risk after 2โ4 weeks in chronic use; switch to SSRIs or CBT for persistent anxiety disorders.
๐ References
- BNF: Lorazepam
- NICE NG185 (2020): Epilepsies: diagnosis and management
- MHRA Drug Safety Update (2022): Benzodiazepines and respiratory depression
- Stahl SM. Prescriberโs Guide, 7th ed. Cambridge University Press, 2022